Impedimed Ltd has released a press release.
PREVENT Trial Results Published - Outstanding Initial Data
Filed with ASX ·
Watch Impedimed's latest callImpedimed (ASX:IPD) Q1 2027 Earnings Call · Replay · Oct 29Read the transcript of Impedimed (ASX:IPD) Q1 2027 Earnings Call6ix hasn’t read this filing yet.
Story so far
Earlier from Impedimed
- Appendix 4C - Quarter ended 30 June 2018
- Appendix 4C - Quarter ended 31 March 2018
- Interim Results of PREVENT Trial
- US FDA 510(k) Clearance for Bilateral Lymphoedema Assessment
- ImpediMed & Sharp HealthCare Sign Agreement for SOZO
Later from Impedimed
- L-Dex Suggested as a New Standard of Care
- Response to ASX Aware Query
- S&P DJI Announces September 2018 Quarterly Rebalance
- ImpediMed Completes Asset Sale of XiTRON Technologies, Inc.
- Appendix 4C - Quarter ended 30 September 2018
Follow Impedimed into a list and get an email when it puts out news.
Follow Impedimed